Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Company Overview

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $2.48 to $2.99
• 50-Day Range: $2.53 to $3.92
• 52-Week Range: $2.23 to $8.92
• Volume: 21,125 shs
• Average Volume: 277,017 shs
• Market Capitalization: $2.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCNI Stock Analysis - Frequently Asked Questions

How have SCNI shares performed this year?

Scinai Immunotherapeutics' stock was trading at $3.35 at the start of the year. Since then, SCNI shares have decreased by 24.5% and is now trading at $2.53.
View the best growth stocks for 2025 here.

How were Scinai Immunotherapeutics' earnings last quarter?

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) released its earnings results on Friday, November, 22nd. The company reported $8.40 earnings per share for the quarter.

When did Scinai Immunotherapeutics' stock split?

Shares of Scinai Immunotherapeutics reverse split on the morning of Tuesday, May 21st 2024. The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Scinai Immunotherapeutics?

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scinai Immunotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 11/22/2024
• Today: 4/04/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCNI
• Previous Symbol: NASDAQ:SCNI
• CIK: 1611747
• Web: www.scinai.com
• Phone: 972-8-930-2529
• Fax: 972-8930-2531
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($239.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,500,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -30.48%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 1.16
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $452,000.00
• Price / Sales: 5.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.84) per share
• Price / Book: -0.26

Miscellaneous

• Outstanding Shares: 934,000
• Free Float: 334,000
• Market Cap: $2.36 million
• Optionable: Not Optionable
• Beta: 2.67